Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04913922
Title Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML (AARON)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ludwig-Maximilians - University of Munich

acute myeloid leukemia


Azacitidine + Nivolumab + Relatlimab

Age Groups: adult | senior
Covered Countries DEU

No variant requirements are available.